Ivonescimab shows four-month survival edge in Harmoni-6 lung cancer trial
TL;DR
Ivonescimab, a PD-1/VEGF bispecific, plus chemotherapy, extended median overall survival by about four months in squamous NSCLC in the Harmoni-6 Phase 3 trial conducted in China; results need confirmation in broader populations and safety signals (bleeding) were noted, with global Harmoni-3 results expected later.
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China CNBC
- Lung Cancer Patients on Drug From China’s Akeso Lived Longer Bloomberg.com
- ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce Pharma
- Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer statnews.com
- Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers BioSpace
Want the full story? Read the original reporting
Read on CNBC